CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal cancers.
  
  OVERVIEW OF ACTIVITY
  Approximately 45,160 people will be diagnosed with gastric or esophageal cancer in the United States in 2019 alone, with nearly 27,220 succumbing to their disease. Published results from ongoing trials continually lead to the emergence of new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care, including the option of clinical trial participation, the practicing medical oncologist must be well informed of these advances.
  
  To bridge the gap between research and patient care, this issue of Oncology Today with Dr Neil Love focusing on advanced gastric and gastroesophageal cancer features a discussion with 2 leading gastrointestinal oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncolo¬gists with the formulation of up-to-date management strategies.
  
  LEARNING OBJECTIVES

  • Compare and contrast the clinical relevance to systemic management of advanced gastric/gastroesophageal cancer of recent pivotal research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastric/gastroesophageal cancer.
  • Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of gastric/gastroesophageal cancer.
  • Describe ongoing research to validate or identify biomarkers predictive of response to anti-PD-1/PD-L1 antibodies, and use this information to guide future trial design and routine clinical practice.
  • Counsel patients regarding the incidence and manifestation of side effects and toxicities associated with systemic agents and regimens commonly used in the management of advanced gastric/gastroesophageal cancer.
  • Devise a rational approach to the potential incorporation of TAS-102 into the treatment algorithm for previously treated locally advanced or metastatic gastric/gastroesophageal adenocarcinoma.
  • Recall the design of ongoing clinical trials evaluating novel investigational agents for gastric/gastroesophageal cancer, and counsel appropriately selected patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THESE CME ACTIVITIES
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Jaffer A Ajani, MD
  Professor of Medicine
  Department of Gastrointestinal Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee and Consulting Agreements: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Lilly, Merck, Taiho Oncology Inc; Contracted Research: Astellas Pharma Global Development Inc, Bristol-Myers Squibb Company, Lilly, Merck, Roche Laboratories Inc, Zymeworks; Data and Safety Monitoring Board/Committee: BEEG (Chinese company).
  
  Joseph Chao, MD
  Assistant Clinical Professor
  Department of Medical Oncology and Therapeutics Research
  Gastrointestinal Cancer Program
  City of Hope Comprehensive Cancer Center
  Duarte, California
  
  Advisory Committee: Daiichi Sankyo Inc, Merck, Taiho Oncology Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boston Biomedical Pharma Inc, Foundation Medicine, Lilly; Contracted Research: Merck, Novonco Therapeutics Inc; Speakers Bureau: Merck.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Lilly.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: February 2019
  Expiration date: February 2020